Solace Therapeutics, Inc., announced today that Stefan De Wachter, MD, PhD will be presenting long-term data from the SOLECT Trial and Denise Elser, MD will be presenting a video presentation of the removal and replacement of the Vesair® Bladder Control Balloon during the 37th Annual AUGS Meeting in Denver, Colorado September 28-30th.
The long-term results presented by Stefan De Wachter, MD, PhD include twelve and twenty-four month data from the SOLECT Trial which is the Company’s second Randomized Controlled Trial of the Vesair Bladder Control System. The results demonstrate that patients continue to experience clinically relevant reduction of urine leakage, episode frequency, and improved quality of life. Prof. De Wachter, from Universitair Ziekenhuis Antwerpen in Edegem, Belgium, is one of several investigators for the multicenter SOLECT Trial.
The video presentation entitled “12 Month In-Dwelling Intravesical Air-Filled Balloon Removal Followed by New Balloon Replacement Per the SUCCESS Clinical Trial Protocol” will be presented by Denise Elser, MD. The video depicts the simplicity of the removal and replacement of the Vesair Bladder Control Balloon in an office setting. “I was delighted to participate in the SUCCESS Trial. The Vesair Bladder Control Balloon is a promising, non-invasive and reversible therapy for women seeking an alternative to conventional treatment options such as pelvic floor muscle training or surgery,” said Denise Elser, MD with the Women’s Health Institute of Illinois.
About Stress Urinary Incontinence and the Vesair Bladder Control System
Women with SUI typically experience transient increases in intravesical pressure during physical movement; for example, when coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethral sphincter to withstand it, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure forces, the Vesair Bladder Control Balloon is designed to reduce rapid increases in bladder pressure through the placement of a compressible air-filled balloon in the bladder. The balloon acts like a “shock absorber” to slow rapid changes in pressure and reduce leakage. The uninflated balloon is placed into the bladder through the urethra and subsequently inflated. Balloon placement is performed as an out-patient procedure that does not require anesthesia. The balloon is intended to remain in the bladder for up to 12 months and is replaced annually. The Vesair Bladder Control System is for investigation use only in the United States and has CE mark approval for distribution within the European Union.
About Solace Therapeutics, Inc.
Solace Therapeutics is an emerging medical technology company primarily focused on a revolutionary non-surgical office-based treatment for symptoms of SUI. SUI affects nearly 30 million women globally and can occur in nearly 40% of all men who have prostate surgery. The cost of caring for patients with incontinence is a significant economic burden on the healthcare delivery system if left untreated. Solace is dedicated to developing value-driven innovations that can help healthcare providers improve patient outcomes, reduce procedure costs, and enhance the quality of life for people whose daily activities are disrupted by their incontinence. Please visit www.solacetx.com to learn more about the Company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005411/en/Business Wire
Last updated on: 28/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.